Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
October 16, 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
Company to host a webinar on the detailed VALIANT results at 12:30 p.m. PT on Saturday, October 26 WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS)...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2024 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant...
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
September 25, 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the UBS Virtual Ophthalmology Day on...
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
September 20, 2024 05:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2024 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant...
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
August 29, 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following September investor conferences: ...
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
August 08, 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
Met the primary endpoint, achieving statistically significant 68% (p<0.0001) reduction in proteinuria compared to placebo in a broad study populationPositive results consistent across all...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 06, 2024 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 01, 2024 07:05 ET
|
Apellis Pharmaceuticals, Inc.
Generated $199.7 million in 2Q 2024 revenues, including $179.1 million in U.S. net product sales $154.6 million for SYFOVRE® (pegcetacoplan injection) $24.5 million for EMPAVELI® (pegcetacoplan) ...
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
July 18, 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second quarter...